Literature DB >> 10820372

Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C.

S Kraus1, Z Fishelson.   

Abstract

Basal cell resistance to lysis by complement C5b-9 complexes depends on extracellular and intracellular protection. Cell membrane regulatory proteins and enzymes interfere with complement activation and intracellular processes of protein phosphorylation and synthesis support cell resistance and damage repair. K562 human erythroleukemic cells treated with sublytic complement doses become protected from lytic doses of complement within 50 min. The early signaling processes leading to cell desensitization to complement-mediated lysis were studied. Treatment with calcium ionophores or phorbol 12-myristate 13-acetate rapidly induced in K562 cells protection from complement as well as synthesis of a large protein complex similar to the large complement-induced protein complex L-CIP induced by sublytic complement. Both ionophore- and complement-induced protection were blocked by treatment with protein kinase C (PKC) inhibitors. Calphostin C, sphingosine and GF109203X abrogated complement-induced protection almost completely, whereas Go6976 inhibited it only partially. Since Go6976 is a selective inhibitor of the conventional PKC type, it is proposed that sublytic complement doses activate both conventional and non-conventional PKC types. Immunofluorescence analysis of K562 cells demonstrated sublytic complement-induced translocation of the conventional PKCalpha and PKCbetaII from the cytoplasm to the plasma membrane. These results indicate that PKC activation is an early obligatory signal in cell desensitization by sublytic C5b-9 or calcium ionophore.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820372     DOI: 10.1002/(SICI)1521-4141(200005)30:5<1272::AID-IMMU1272>3.0.CO;2-9

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis.

Authors:  S Kraus; R Seger; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

2.  CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.

Authors:  C H Nielsen; H V Marquart; W M Prodinger; R G Leslie
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

3.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

4.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

Review 5.  The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription.

Authors:  Matthew Fosbrink; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  Emission of membrane vesicles: roles in complement resistance, immunity and cancer.

Authors:  David Pilzer; Olivier Gasser; Oren Moskovich; Jurg A Schifferli; Zvi Fishelson
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

7.  Retinal pigment epithelial cell death by the alternative complement cascade: role of membrane regulatory proteins, calcium, PKC, and oxidative stress.

Authors:  Ping Yang; Peter Baciu; Brittany C Parker Kerrigan; Menna Etheridge; Eric Sung; Brett A Toimil; Jacob E Berchuck; Glenn J Jaffe
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-06       Impact factor: 4.799

Review 8.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 9.  Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets.

Authors:  Catherine B Xie; Dan Jane-Wit; Jordan S Pober
Journal:  Am J Pathol       Date:  2020-03-16       Impact factor: 4.307

10.  Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection.

Authors:  Kazunori Murata; William M Baldwin
Journal:  Transplant Rev (Orlando)       Date:  2009-04-10       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.